James S. MacDonald, Ph.D.
During a career that has spanned more than three decades, Dr. MacDonald has brought hundreds of new molecular entities forward from discovery into development, over thirty of which have become globally registered, major drugs, including Vasotec®, Zocor®, Primaxin®, Clinoril®, Pepcid®, Fosamax®, Clarinex®, Nasonex®, and Vitorin®, among others. Until his retirement at the end of 2008, he was Executive Vice President of Preclinical Development for Schering-Plough Research Institute (SPRI), the pharmaceutical development arm of Schering Corporation. Joining SPRI in 1994, over the next 14 years Dr. MacDonald played a leading role in building one of the most capable drug development organizations in the world. In addition to his line responsibility for Drug Safety and Metabolism, as co-chairman of SPRI’s Early Development Committee he directed the activities surrounding the movement of drug candidates from discovery research into and through the development process. From 1977 until 1994, Dr. MacDonald held positions of increasing responsibility at Merck, including Executive Director of Toxicology. He received his Ph.D. in toxicology in 1975 from the University of Cincinnati and joined Merck after completing a post-doctoral fellowship at Vanderbilt University. He became a diplomate of the American Board of Toxicology in 1980.

multi-readout, repeat-dose
DILI screening
DILI screening

Hurel microlivers afford better prediction than 3D

Toxicology Research
Long-enduring infectious liver disease platform
Toxicity Ratios*
A new marker for hepatotoxic chronicity

*patent pending
a new, patent-pending
efflux transport
assay method
Superior intrinsic clearance
and biotransformation of
low-turnover drugs